| Entry |
| ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Name | Lafutidine (JP18/INN); Protecadin (TN) | ||||||||||
| Formula | C22H29N3O4S | ||||||||||
| Exact mass | 431.1879 | ||||||||||
| Mol weight | 431.5484 | ||||||||||
| Structure |  | ||||||||||
| Class | Gastrointestinal agent DG01975 Agents for peptic ulcer DG01481 Histamine receptor H2 antagonist Metabolizing enzyme substrate DG01644 CYP2D6 substrate DG01633 CYP3A/CYP3A4 substrate DG02913 CYP3A4 substrate | ||||||||||
| Remark |
| ||||||||||
| Efficacy | Anti-ulcerative, H2 receptor antagonist | ||||||||||
| Target | HRH2 [HSA:3274] [KO:K04150] | ||||||||||
| Pathway |
| ||||||||||
| Metabolism | Enzyme: CYP3A4 [HSA:1576], CYP2D6 [HSA:1565] | ||||||||||
| Interaction | |||||||||||
| Structure map |
| ||||||||||
| Brite | Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] A ALIMENTARY TRACT AND METABOLISM A02 DRUGS FOR ACID RELATED DISORDERS A02B DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) A02BA H2-receptor antagonists A02BA08 Lafutidine D01131 Lafutidine (JP18/INN) <JP> Therapeutic category of drugs in Japan [BR:br08301] 2 Agents affecting individual organs 23 Digestive organ agents 232 Peptic ulcer agents 2325 H2 blockers D01131 Lafutidine (JP18/INN) Drug groups [BR:br08330] Gastrointestinal agent DG01975 Agents for peptic ulcer DG01481 Histamine receptor H2 antagonist D01131 Lafutidine Metabolizing enzyme substrate DG01644 CYP2D6 substrate D01131 Lafutidine DG01633 CYP3A/CYP3A4 substrate DG02913 CYP3A4 substrate D01131 Lafutidine Drug classes [BR:br08332] Gastrointestinal agent DG01481 Histamine receptor H2 antagonist D01131 Lafutidine Target-based classification of drugs [BR:br08310] G Protein-coupled receptors Rhodopsin family Histamine HRH2 D01131 Lafutidine (JP18/INN) <JP> Drugs listed in the Japanese Pharmacopoeia [BR:br08311] Chemicals D01131 Lafutidine D01131 Lafutidine tablets New drug approvals in Japan [br08318.html] Drugs with new active ingredients D01131 New drug approvals in the USA, Europe and Japan [br08328.html] Approval dates by FDA, EMA and PMDA D01131 Drug metabolizing enzymes and transporters [br08309.html] Drug metabolizing enzymes D01131 | ||||||||||
| Other DBs |
| ||||||||||
| KCF data | ATOM 30 1 C1x C 11.2700 -29.7500 2 C1x C 11.2700 -31.1500 3 C1x C 12.4600 -31.8500 4 N1y N 13.7200 -31.1500 5 C1x C 13.7200 -29.7500 6 C1x C 12.4600 -29.0500 7 C1b C 14.9100 -31.8500 8 C8y C 16.1000 -31.1500 9 C8x C 17.2900 -31.8500 10 C8y C 18.5500 -31.1500 11 N5x N 18.5500 -29.7500 12 C8x C 17.3600 -29.0500 13 C8x C 16.1000 -29.7500 14 O2a O 19.7400 -31.8500 15 C1b C 20.9300 -31.1500 16 C2b C 22.1200 -31.8500 17 C2b C 23.5200 -31.8500 18 C1b C 24.7100 -31.1500 19 N1b N 25.9000 -31.8500 20 C5a C 27.0900 -31.1500 21 C1b C 28.2800 -31.8500 22 S4a S 29.4700 -31.1500 23 C1b C 30.6600 -31.8500 24 C8y C 31.8500 -31.1500 25 O3c O 29.4700 -29.7500 26 O5a O 27.0900 -29.7500 27 C8x C 32.2700 -29.8200 28 O2x O 32.9700 -31.9900 29 C8x C 34.0900 -31.1500 30 C8x C 33.6700 -29.8200 BOND 32 1 1 2 1 2 2 3 1 3 3 4 1 4 4 5 1 5 5 6 1 6 1 6 1 7 4 7 1 8 7 8 1 9 8 9 2 10 9 10 1 11 10 11 2 12 11 12 1 13 12 13 2 14 8 13 1 15 10 14 1 16 14 15 1 17 15 16 1 18 16 17 2 19 18 19 1 20 18 17 1 21 19 20 1 22 20 21 1 23 21 22 1 24 22 23 1 25 23 24 1 26 22 25 2 27 20 26 2 28 27 24 2 29 24 28 1 30 28 29 1 31 29 30 2 32 27 30 1 |